Soft tissue sarcoma survival statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Survival

Survive soft tissue sarcoma for 10 or more years, 2009-2013, England

 

Age

Age that soft tissue sarcoma survival is highest, 2001-2005, UK

 

77% of men survive soft tissue sarcoma for at least one year, and this falls to 55% surviving for five years or more, as shown by age standardised Open a glossary item relative survival for patients diagnosed with soft tissue sarcoma during 2001-2009 in the UK.[1] Survival for women is lower, with 73% surviving for one year or more, and 52% surviving for at least five years.

Soft Tissue Sarcoma Age-Standardised One-, Five- and Ten-Year Relative Survival, Adults (Aged 15-85+), UK, 1996-2009

Ad Hoc Sex 1-Year Survival (%) (2005-2009) 5-Year Survival (%) (2001-2005) 10-Year Survival (%) (1996-2000)
Men Relative survival 77.0 55.0 46.0
95% LCL 76.0 54.0 44.0
95% UCL 78.0 57.0 48.0
Women Relative survival 73.0 52.0 43.0
95% LCL 72.0 51.0 42.0
95% UCL 74.0 53.0 45.0
Adults Relative survival 75.0 53.0 45.0
95% LCL 74.0 52.0 43.0
95% UCL 76.0 54.0 46.0

95% LCL and 95% UCL are the 95% lower and upper confidence limits

Five- and ten-year survival is predicted using an excess hazard statistical model.

Soft tissue sarcoma survival continues to fall beyond five years after diagnosis. 46% of men and 43% of women survive their disease for ten years or more, as shown by age-standardised relative survival for patients diagnosed with soft tissue sarcoma during 1996-2000 in the UK.[1]

See also

Find out more about the counting and coding of this data

Cancer survival statistics for common cancers in the UK

References

  1. Data were provided by Public Health England Knowledge and Intelligence Team (West Midlands), on request, 2013.

About this data

Data is for: UK, 1996-2009. See source for ICD codes and other data specifics.

Last reviewed:

Five-year survival for soft tissue sarcoma is generally higher in younger men and women and decreases with increasing age. However, there is also a small dip in survival for young people. For patients diagnosed with soft tissue sarcoma in the UK during 2001-2005, five-year relative survival in men ranges from 69% in 35-39 year-olds to 36% in those aged 85+.[1] In women, five-year survival ranges from 73% in 25-29 year olds to 27% in those aged 85+.

Soft Tissue Sarcoma, Five-Year Relative Survival by Age, UK, 2001-2005

See also

Find out more about the counting and coding of this data

Soft tissue sarcoma incidence statistics by age

Cancer survival statistics for common cancers in the UK

References

  1. Data were provided by Public Health England Knowledge and Intelligence Team (West Midlands), on request, 2013.

About this data

Data is for: UK, 2001-2005. See source for ICD codes and other data specifics.

Last reviewed:

Five-year relative survival for soft tissue sarcoma in men in England (58%) is similar to the average for Europe (59%). Wales (64%), Scotland (58%) and Northern Ireland (62%) are also similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 46% (Bulgaria) to 69% (Bulgaria).[1] 

Five-year relative survival for soft tissue sarcoma in women in England (57%), Scotland (54%) and Northern Ireland (54%) are below the average for Europe (61%). Wales (58%) is similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in women ranges from 51% (Estonia) to 67% (Spain).[1] 

Soft tissue sarcoma (C38.0, C47, C49), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

See also

Cancer diagnosis and treatment

Soft tissue sarcoma incidence

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, soft tissue sarcoma (C38.0, C47, C49).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Cancer stats explained

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Join the conversation and follow @CRUKHCPs for news, updates and opinion.

 @CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.